


CANNABINOIDS CLINICAL RESEARCH



CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS

Pioneers of groundbreaking research for
alternative next-level medicine



The following presentation contains proprietary information about **CBIH**, a public company listed on the OTC Markets. The information includes, among other matters, financial information, marketing concepts and strategies, marketing plans, and designs for trade and trademarks. By reading this executive summary, you agree all the information is confidential and the property of **CBIH**. You agree you will not disclose the information to any other person without the written authorization of **CBIH**. You further agree you will not use the information for any purpose except the evaluation of the business plan for possible investment in the business venture it describes.

These financial estimates are based upon management's opinion as to reasonable results assuming the projects materialize. There can be no assurance that any of these results will be obtained.

WELCOME TO CBIH

Working in medical cannabis research for 15 years **and NOW prepared to take it to the next level... with you**, health professionals, and the patients that need a new and better option in their recovery journey



In all, PubMed.gov now cites over 42,500 scientific publish studies on cannabis, developed by Health Institutions, Labs, Scientific Groups, Government Entities, various countries, Universities, and Cannabinoids Researchers Around The World. And the studies keep increasing...

CANNABINOIDS

Cannabinoids are the main chemical compounds of the Cannabis plant. These include THC, CBD, CBC, CBN, and CBG.

GOOD NEWS

There are several cancers (breast cancer, prostate cancer, leukemia, skin cancer, pheochromocytoma, and lymphoma), that in experimental situations can be killed by cannabinoids.

OUR PROJECT

Research of the **effect of cannabinoids in the treatment of medical conditions**, including Cancer, COVID, opioid addiction, and chronic pain, among others.



CBG

Anti-inflammatory, neuroprotective, and neuromodulatory, antibacterial, antiviral, anti-proliferative, anti-nausea and mental health regulator.

CBC

Bone stimulant, anti-fungal, anti-bacterial, anti-inflammatory, analgesic

CBN

Immunomodulatory, anti-inflammatory, antibiotic, somniferous, analgesic, antioxidant

THCV

Appetite regulation, obesity management, type 2 diabetes management, anticonvulsant, metabolic syndrome treatment

THC

Analgesic, anti-inflammatory, anxiolytic, anti-emetic, antitumoral antioxidant, decreases intraocular pressure

Delta-8-THC:

Relaxation, euphoria, pain relief, anxiolytic, analgesic, antiemetic

CBD

Anti-inflammatory, neuroprotective, immunomodulatory, antioxidant, anticonvulsant, anxiolytic, antitumoral

CBGA

Antiviral, anti-inflammatory, antitumoral, sedative, may support heart health and metabolic disorders



What's the advised temperature for vaping cannabinoids?



TEMP °C	CANNABINOIDS	TREATMENTS	TEMP °F	+COMPUNDS	TREATMENTS
BP 220 °C 220	Cannabichromene CBC Active State	<ul style="list-style-type: none"> • Anti-proliferative • Anti-bacterial • Bone Stimulant • Anti-inflammatory • Analgesic 	BP 428 °F 428	+ pulegone + quercetin = <i>Smoke & Vapour</i>	Sedative, Anti-pyretic AChE Inhibitor, and Insecticide, Anti-oxidant, Anti-neoplastic, Anti-viral, Anti-mutagenic, and a CBD synergistic compound
BP < 220 °C 220	Tetrahydrocannabivarin THCV Active State (C ₂₁)	<ul style="list-style-type: none"> • Euphoric, Anti-THC • Analgesic • Anti-diabetic • Anorectic • Bone Stimulant 	BP < 428 °F 428	+ α-terpineol = <i>Smoke & Vapour</i> = Ready to consume	Anti-anxiety, Anti-oxidant, Anti-microbial, Sedative, Anti-protozoal, Anti-biotic, and Anti-malarial. <i>(Reduce toxins by consuming)</i>
BP - BENZENE 205	Hydrocarbons SMOKE Benzene, and more	*** WARNING *** Toxic Vapours 200 °C 392 °F Harmful toxins begin: <i>Reduce Toxins in Cannabis</i>	BP - BENZENE 401	+ terpinen-4-ol = <i>Smoke & Vapour</i> + borneol	Anti-biotic, AChE Inhibitor, and may increase memory. Traditional Chinese Medicine, used as a "moxa."
BP - THEORY 195	Cannabielsoin CBE Active State	<i>CBE increases with prolonged exposure to heat, oxygen & light. Likely to contain cannabinoids other than CBE. Showing the Maximum Medical Temp.</i>	BP - THEORY 383	+ linalool = <i>Nighttime Meds</i> = <i>Club Favourite</i>	Powerful Sedative, reduces Anxiety, Anti-stress, Anti-microbial, Anxiolytic, Immune Potentiator, and a CBD synergistic compound.
BP 185 °C 185	Cannabinol CBN Active State	<i>CBN increases with prolonged exposure to heat, oxygen & light.</i> <ul style="list-style-type: none"> • Anti-spasmodic • Anti-insomnia • Analgesic 	BP 365 °F 365	+ cannflavin A = <i>Nighttime Meds</i> = <i>NORML Favourite</i>	Prostaglandin E2 Inhibitor, Cyclooxygenase Inhibitor, and Lipoxygenase Inhibitor <i>(pending device temp. error)</i>
BP 177 °C 175	Tetrahydrocannabinol THC Active Δ8 (C ₂₁)	<i>The Δ8 cannabinoid mode lead to Hebrew University's HU-210.</i> <ul style="list-style-type: none"> • 10% as psychoactive Δ9 • Neuroprotective • Anti-emetic 	BP 351 °F 347	+ eucalyptol + limonene + p-cymene + apigenin	Anti-viral, Anti-biotic, Dietary Anti-cancer tool. Anti-biotic, Anti-candidal. Opioid receptor Antagonist.
160° - 180 °C 165	Cannabidiol CBD Active State	Most conditions listed EXCLUDING the following <ul style="list-style-type: none"> • Anti-insomnia • Anti-fungal • Anti-anorectic 	320° - 356 °F 329	+ β-myrcene = <i>Daytime Meds</i> + Δ-3-carene	Anti-biotic, and Anti-mutagenic. Analgesic, and Anti-inflammatory with slight Sedative effects.
BP 157 °C 155	Tetrahydrocannabinol THC Active Δ9 (C ₂₁)	<ul style="list-style-type: none"> • Anti-inflammatory • Anti-anorectic • Anti-emetic • Anti-proliferative • Anti-oxidant 	BP 315 °F 311	+ α-myrcene = <i>Daytime Meds</i> = <i>3rd Med Vapour</i>	With CBD treats MRSA, Anti-inflammatory, Bone Stimulant, Anti-biotic, Bronchodilator, Cytotoxic, and may increase memory.
100° - 145 °C 140	Cannabichromene CBCA Acidic State	1) Req. 60 mins in the oven** 2) When eaten <i>unheated</i> : <ul style="list-style-type: none"> • Anti-bacterial • Anti-fungal • Not full elucidated 	212° - 298 °F 284	+ β-sitosterol = <i>2nd Med Vapour</i> ** <i>CBC conversion</i>	5-α-reductase Inhibitor, Anti-inflammatory and Chronic Edema treatment <i>(Avoid if Breastfeeding)</i> Pregnant <i>Increases CBD and CBE</i>
80° - 135 °C 130	Cannabidiol CBDA Acidic State	1) Req. 60 mins in the oven** 2) When eaten <i>unheated</i> : <ul style="list-style-type: none"> • Anti-proliferative • Anti-inflammatory • Not full elucidated 	176° - 275 °F 266	+ β-caryophyllene = <i>1st Med Vapour</i> ** <i>CBC conversion</i>	Cytoprotective, Neuroprotective, Analgesic, Anti-malarial, Anxiolytic, and Anti-inflam- matory. <i>(Increases CBD and CBE)</i>
60° - 125 °C 120	Tetrahydrocannabinol THCA Acidic State	1) Req. 60 mins in the oven... 2) When eaten <i>unheated</i> : <ul style="list-style-type: none"> • Anti-inflammatory • Anti-epileptic • Anti-proliferative 	146° - 251 °F 248	Cannabigerol + CBG Acidic State	<i>(Conversion occurs while curing)</i> <ul style="list-style-type: none"> • Anti-inflammatory • Analgesic, Anti-bacterial • Anti-fungal, Bone Stimulant • Anti-proliferative



COMPETITORS ...

Pfizer Bets On Medical Cannabis With \$6.7 Billion Acquisition

“Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for \$100 per share, in cash, for a total equity value of approximately \$6.7 billion. The acquisition was completed by way of a merger in accordance with Delaware law and, as a result of the acquisition, Arena became a wholly-owned subsidiary of Pfizer.”

Friday, March 11, 2022

Arena Pharmaceuticals is a biotech company with one pipeline dedicated to cannabinoid-type therapeutics. The core of its cannabis operation consists of Olorinab (APD371), an investigational, oral, full agonist of the cannabinoid type 2 receptor (CB2), which aims to treat patients with diseases affecting the stomach and intestine.



MEDICINE FINDS ANSWERS IN NATURE

A Little History of Medicine

In 1928 Dr. Alexander Fleming returned from a holiday **to find mold growing on a Petri dish of Staphylococcus bacteria**. He noticed the mold seemed to be preventing the bacteria around it from growing. He soon identified that **the mold produced a self-defense** chemical that could kill bacteria. **He named the substance penicillin.**



THE ENDOCANNABINOID SYSTEM

PRESYNAPTIC
(SENDING NEURON)

Naturally occurring compounds

- Anandamide and 2-AG
- The “Keys”

Molecules attach to receptors

- The “Locks”
- CB1 receptor in many areas of the brain
- CB2 receptor mainly in the immune system

The result is inhibiting nerve action

- Part of the braking system in the brain
- Multiple roles in the immune system



NEUROTRANSMITTERS

CANNABINOIDS

THC




CANNABINOID RECEPTOR

RECEPTORS

LIPID PRECURSORS
(FAT CELLS)

PRESYNAPTIC
(RECEIVING NEURON)



We are a global team of innovators



Scientific Experts

Ph.D. in Science, Professional biologists, and Cannabis experts

We understand the plant

Health Professionals

Oncologists, MDs, Psychologists, Radiologists.

We understand the human body

Legal and Operations

Lawyers, Accountants, Marketing experts, and Executives.

We understand results

YOU

Investor, Patient

With a Powerful Role in Our Future

Our team manifesto... Better health moves the human **spirit**, heals the **body**, and keeps the **mind** focused on the art of living well

YOU


Investor of
the future




Brian Cuban
Director



John Jones
Treasurer and Director



Barry J Miller
Attorney at Law -
Securities



Stephen Khoury
Corp. Attorney



Dr. Jose Torres Torres
National Medical
Director



Dante Picazo
CEO



Jorge Verar
CPA - Certified Public
Accountant



Victor Mokuolu, CPA
PCAOB



Dr. Ugochi Ekeocha
Master of Health Care
Administration



Jennifer Salguero
Ph.D. in Sciences



Katerin Osuna R.
Master - Communication



Dr. Ibeth Corrales
Doctorate in Dental
Surgery



**Dr. Stephanie
Hartmann**
Doctor, MD



Nancy Duarte
Ph. D. in Biology



Ana Maldonado
Pharmaceutical
chemist



Rosangel Andrades
Doctor, MD



**Dr. Yesiree
Baptista**
Doctor, MD



Nancy Rodrigues Das Fontes
Pharmaceutical chemist



Viviana Camacho
Comptroller - Magister
Scientiarum in Administration



Mariana Sardi
Administrator - Project
Coordinator



Tivisay Diaz
BA in
Administration



Bethania Molina
Administrative
Assistant





WHY DO WE DO IT'?

... Cancer, Multiple sclerosis,
Alzheimer, Epilepsy, Chronic pain...

To create a better quality of life!




*At least 71.8% and as many as 80% of overdose deaths involve **opioids**.*

In 2023, **1,958,310 new cancer cases** and **609,820 cancer deaths** are projected to occur in the United States.

Behind a scar, there is a human being with the desire to smile again

Cannabinoids and Cancer Treatment: Cannabinoids are the main chemical compounds of the Cannabis plant. These include THC, CBD, and CBG. These compounds have shown to be effective in helping cancer patients reduce the side effects of chemotherapy (nausea, vomiting, loss of appetite, weight loss, pain)





The global CBD oil and CBD consumer health market is expected to grow from \$39.54 billion in 2022 to \$49.72 billion in 2023 at a compound annual growth rate (CAGR) of 25.75%.

Cannabidiol (CBD) Market to Reach [USD 55,791.3 Million by 2028](#) | With a CAGR of 47.49%

BIOAVAILABILITY

The extent or fraction of a substance or **drug that becomes completely available** to its intended biological destination(s)

Drug pharmacology

When administered orally, the drug faces different barriers.

First, it passes through the acidic gastric pH
Then it reaches the intestine (it can be metabolized by enzymes) and is absorbed into the capillaries which then drain into the liver.
In the liver, the drug is metabolized and transformed (Hepatic First Pass Effect)

**AS A RESULT, THE
BIOAVAILABILITY DECREASES**




How can we improve the drug bioavailability?


Cannabis extracts are highly lipophilic molecules and can have immiscibility in some presentations (edible infusions, beverages, creams, and other infused products), therefore, there is a need for a suitable emulsification method.

Nanoemulsions work as small droplets that provide a higher degree of clarity, stability, and low viscosity.


A study showed that CBD nanoemulsions greatly enhanced the absorption of CBD and improved its bioavailability.



Standard Oil
10% or less absorption



Liposomal Microemulsion
100-1000 Nanometer
20% Absorption



Nano-Sized Microemulsion
25 Nanometer (Avg)
50% Absorption Maximum Bioavailability



THE ANSWER IS Nanoemulsions

The tiny size of the nanoemulsion droplets and their ability to solubilize very hydrophobic drugs provide an **opportunity to dramatically increase the rate of drug dissolution** and thus the expected systemic bioavailability.



ARTIFICIAL INTELLIGENCE IN MEDICINE

Thanks to advances in computing and hardware, and the emergence of deep learning and artificial neural networks, **AI programs are becoming increasingly present in clinical practice.** These have been used for clinical and genomic diagnostics, chronic disease management, and sophisticated surgical robots.



How Artificial Intelligence is Revolutionizing Discovery, Manufacturing, and medicinal cannabis?

IA programs are able to understand, adapt, react, and provide answers according to a specific context. **This would help to optimize the processes of scientific research** and formulation of new medical products.



“AI will allow the scientific community to obtain in 1 year of research, what traditional methodologies would normally learn in 30 years”

These programs under the human supervision of a team of medical professionals, chemists, biologists, and engineers have the ability to **collect a large amount of information from many sources in seconds** and provide solutions/customized answers

It could track demand to improve production and could be used for content marketing and compliance with media laws. **And it could lower the cost of building brands** and reduce retail labor costs

Some News:

“AI suggested **40,000** new possible chemical weapons in just six hours”

“Artificial intelligence model finds potential drug molecules a **thousand times faster**”

“Artificial Intelligence (AI) Healthcare Market size was valued at USD 6.95 Billion in 2021 and is expected to grow at a **CAGR of 40.51 percent from 2022 to 2029**, reaching nearly USD 97.23 Billion.”

We are in a time when anyone can generate thousands of new molecules through AI, ***what matters is who does it to a significant ethical standard.***

ARTIFICIAL INTELLIGENCE

A program that can sense, reason, act, and adapt

MACHINE LEARNING

Algorithms whose performance improve as they are exposed to more data over time

DEEP LEARNING

Subset of machine learning in which multilayered neural networks learn from vast amounts of data

from the microscope to the market

2023

2028





The information gathered from our clinical research **will be used to either approve or deny the efficacy of our alternative OTC medications & treatments.**

Ultimately, we will ensure the scientific integrity of data and protect the rights, safety, and well-being of subjects enrolled in our mini-clinical trials.

Phase I

Establish human pharmacology & determine safe dose
Effectiveness of the drug is secondary

Phase II


Establish activity of the drug in a specific disease.
Confirm safe and tolerable dose
Establish nature and severity of toxicity
Possibly confirm pharmacology

Phase III

See if the new drug is better than the established therapy
See if drug is better than placebo
Establish activity of the drug
Reconfirm toxicity severity and nature in a larger population

Phase IV

Any rare or long-term effects of the drug can be observed in a much larger population of patients and over a much longer period of time



CBIH proposes a series of data medicinal research that falls outside of the traditional clinical trial setting, as our primary aim is not to seek FDA approval through a process that would probably take approximately 10 to 15 years and cost millions of dollars to produce FDA-approved drugs/medications.


In contrast, our proposed projects have as their cornerstone the understanding and knowledge of the palliative properties that medical cannabis offers to the human body and how it allows it to restore balance through the ubiquitous endocannabinoid system. **We expect that our formulations will allow us to understand the properties and impact of cannabinoids to restore homeostasis in the organism** and strengthen the immune system to improve symptoms, prevent consequences, optimize treatments, and provide a better quality of life for patients with chronic conditions, inflammatory diseases, and other pathologies.



Our collected data will also be utilized to create allegiances with pharmaceutical companies, medical institutions, or countries where our formulations can be utilized not as the last resource, but instead as a mainstream first-choice medication for those whom traditional medication has forgotten.

By 2026, the company **will have developed** capsules, ointments, syrups, oils, suppositories, orally disintegrating tablets, and many more nutraceuticals to aid in the treatment of different medical conditions.





Orthocann

Is an injectable nanoemulsion for intra-articular administration, combining 25 mg of Cannabichromene (CBC) and 45 mg of Cannabigerol (CBG), two phytocannabinoids with notable pharmacological properties.



NEUROCANN

Is a specialized formulation combining broad-spectrum Cannabidiol (CBD) oil derived from the cannabis plant, and prebiotics. The active ingredients include cannabinoids such as Cannabigerol (CBG), Cannabichromene (CBC), terpenes, and flavonoids..



VITAPANCREATIC CANCER

What is it?

VITAPANCREATICCANCER formulation targets advanced pancreatic cancer through a highly synergistic mechanism involving cannabinoids, terpenes, and flavonoids, all encapsulated within a nanoemulsion system for enhanced bioavailability and precision targeting of cancer cells.



VITABREASTCANCER



What is it?

is a cutting-edge formulation developed to treat breast cancer, especially in early stages, by integrating phytocannabinoids into advanced nanopatform technology. This innovative approach is designed to precisely target breast cancer cells, inhibiting tumor growth by modulating key molecular pathways involved in cancer progression.



COVIDIOL SYRUP & COVIDIOL CAPSULES

What is it?

The proposal consists of syrup and capsules treatments applied at different stages of the disease caused by SARS- CoV-2 with the aim of modulating the patient's immune response using phytocannabinoid compounds.



CANNAWELL




What is it?

A signature formulation in drops to allow good absorption of CBD for the **treatment of seizures in case of epilepsy** and associated syndromes



CannaSutra

A signature formulation in soft gels to help with **erectile dysfunction**. CannaSutra is ideal to enhance the sex drive and libido, achieving the connection between sexual desire and reproductive man anatomy while increasing sexual stamina with added health and longevity benefits.



CannaValentine



CannaValentine provides relief from vaginal dryness and the annoyance and pain it can cause. As a libido enhancer, CannaValentine improves emotional well-being while boosting women's sexual desires naturally.



CANNANOMA

Chemotherapy Cream

This ointment is formulated to act as a topical **anticancer treatment** applied to the affected area in order to relieve the symptoms. CBD, CBG, CBC, and THC inhibit the VEGF protein and related enzymes of the cancer-causing cells.



DISTENDA

For Nighttime Recovery

What is it?

These oral disintegrating strips are ideal to obtain a **sedative effect** and **fight sleep apnea, insomnia, or other sleep disorders**. The rapid dissolution of the strips will allow a fast effect.

Distenda

For Nighttime Recovery

CBD ORAL DISINTEGRATING STRIPS


Ideal to obtain a sedative effect and fight sleep apnea, insomnia, or other sleep disorders.

SALES 2025 -2027

PRODUCT	2025		2026		2027		2028		TOTAL			
	PRICE	UNITS PER YEAR	50% INCREASE	%	20% INCREASE	%	15% INCREASE	%				
VITACANCER	\$99.00	15,000	\$ 1,485,000	25.98%	\$ 7,425,000	24.6%	\$ 14,850,000	24.1%	\$ 17,077,500	21.9%	\$ 40,837,500	23.3%
MELANOMA OINTMENT	\$ 79.00	10,000	\$ 790,000	13.82%	\$ 3,950,000	13.1%	\$ 7,900,000	12.8%	\$ 9,085,000	11.6%	\$ 21,725,000	12.4%
COVID - SYRUP	\$ 12.00	10,000	\$ 120,000	2.10%	\$ 600,000	2.0%	\$ 1,200,000	2.0%	\$ 1,380,000	1.8%	\$ 3,300,000	1.9%
COVID - CAPSULES	\$ 12.00	10,000	\$ -	0.00%	\$ 120,000	0.4%	\$ 240,000	0.4%	\$ 276,000	0.4%	\$ 636,000	0.4%
IBUCAN	\$ 14.00	10,000	\$ 140,000	2.45%	\$ 700,000	2.3%	\$ 1,400,000	2.3%	\$ 1,610,000	2.1%	\$ 3,850,000	2.2%
Pharma Melts	\$ 49.00	10,000	\$ -	0.00%	\$ 490,000	1.6%	\$ 980,000	1.6%	\$ 1,127,000	1.4%	\$ 2,597,000	1.5%
HempNopiate	\$ 49.00	10,000	\$ 490,000	8.57%	\$ 2,450,000	8.1%	\$ 4,900,000	8.0%	\$ 5,635,000	7.2%	\$ 13,475,000	7.7%
CannaWell	\$ 69.00	10,000	\$ 690,000	12.07%	\$ 3,450,000	11.4%	\$ 6,900,000	11.2%	\$ 7,935,000	10.2%	\$ 18,975,000	10.8%
PTSD	\$ 39.00	10,000	\$ -	0.00%	\$ 390,000	1.3%	\$ 780,000	1.3%	\$ 897,000	1.1%	\$ 2,067,000	1.2%
SHINGLES	\$ 69.00	10,000	\$ -	0.00%	\$ 690,000	2.3%	\$ 1,380,000	2.2%	\$ 1,587,000	2.0%	\$ 3,657,000	2.1%
ANXIDIOL	\$ 39.00	10,000	\$ -	0.00%	\$ 390,000	1.3%	\$ 780,000	1.3%	\$ 897,000	1.1%	\$ 2,067,000	1.2%
NEUROCAN/DEPRESSION	\$ 39.00	10,000	\$ -	0.00%	\$ 390,000	1.3%	\$ 780,000	1.3%	\$ 897,000	1.1%	\$ 2,067,000	1.2%
MULTIPLE SCLEROSIS	\$ 69.00	10,000	\$ -	0.00%	\$ 690,000	2.3%	\$ 1,380,000	2.2%	\$ 1,587,000	2.0%	\$ 3,657,000	2.1%
MENOPAUSE	\$ 49.00	10,000	\$ -	0.00%	\$ 490,000	1.6%	\$ 980,000	1.6%	\$ 1,127,000	1.4%	\$ 2,597,000	1.5%
35 PLUS/ PREGNANCY	\$ 49.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 490,000	0.8%	\$ 563,500	0.7%	\$ 1,053,500	0.6%
CANNAVALENTINE	\$ 39.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 390,000	0.6%	\$ 448,500	0.6%	\$ 838,500	0.5%
CANNACOLAGEN	\$ 49.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 490,000	0.8%	\$ 563,500	0.7%	\$ 1,053,500	0.6%
CANNADENT	\$ 5.99	10,000	\$ -	0.00%	\$ -	0.0%	\$ 59,900	0.1%	\$ 68,885	0.1%	\$ 128,785	0.1%
VITA BREAST CANCER	\$ 99.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 990,000	1.6%	\$ 1,138,500	1.5%	\$ 2,128,500	1.2%
VITA PANCREATIC CANCER	\$ 99.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 990,000	1.6%	\$ 1,138,500	1.5%	\$ 2,128,500	1.2%
ORTHOCAIN	\$ 19.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 190,000	0.3%	\$ 218,500	0.3%	\$ 408,500	0.2%
EWING SARCOMA	\$ 99.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 990,000	1.6%	\$ 1,138,500	1.5%	\$ 2,128,500	1.2%
ALZHEIMER	\$ 49.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ 490,000	0.8%	\$ 563,500	0.7%	\$ 1,053,500	0.6%
DIABETES	\$ 59.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ -	0.0%	\$ 590,000	0.8%	\$ 590,000	0.3%
GLAUCOMA	\$ 59.00	10,000	\$ -	0.00%	\$ -	0.0%	\$ -	0.0%	\$ 590,000	0.8%	\$ 590,000	0.3%
CLINICAL TRIALS/ WELLNESS CENTER			\$ 2,000,000	35.00%	\$ 8,000,000	26.5%	\$ 12,000,000	19.5%	\$ 20,000,000	25.6%	\$ 42,000,000	23.9%
TOTAL SALES		255,000	\$ 5,715,000	100%	\$ 30,225,000	100.0%	\$ 61,529,900	100.0%	\$ 78,139,385	100.0%	\$ 175,609,285	100.0%
COST OF SALES:												
Marketing		\$ 1,714,500		30.0%	\$ 9,067,500	30.0%	\$ 18,458,970	30.0%	\$ 23,441,816	30.0%	\$ 52,682,786	30.0%
Shipping		\$ 57,150		1.0%	\$ 1,209,000	4.0%	\$ 1,722,837	2.8%	\$ 2,187,903	2.8%	\$ 5,176,890	2.9%
Packaging/Labeling		\$ 57,150		1.0%	\$ 1,511,250	5.0%	\$ 1,722,837	2.8%	\$ 2,187,903	2.8%	\$ 5,479,140	3.1%
Maintenance / Equipment		\$ 11,430		0.2%	\$ 272,025	0.9%	\$ 492,239	0.8%	\$ 703,254	0.9%	\$ 1,478,949	0.8%
Payroll		\$ 600,000		10.5%	\$ 2,200,000	7.3%	\$ 4,200,000	6.8%	\$ 5,000,000	6.4%	\$ 12,000,000	6.8%
Rent Expenses/Clinics		\$ 120,000		2.1%	\$ 192,000	0.6%	\$ 240,000	0.4%	\$ 336,000	0.4%	\$ 888,000	0.5%
Software Expenses		\$ 10,000		0.2%	\$ 10,000	0.0%	\$ 10,000	0.0%	\$ 10,000	0.0%	\$ 40,000	0.0%
Accounting Fees		\$ 75,000		1.3%	\$ 75,000	0.2%	\$ 75,000	0.1%	\$ 75,000	0.1%	\$ 300,000	0.2%
Legal Fees		\$ 120,000		2.1%	\$ 120,000	0.4%	\$ 120,000	0.2%	\$ 120,000	0.2%	\$ 480,000	0.3%
Insurance		\$ 3,500		0.1%	\$ 12,000	0.0%	\$ 18,000	0.0%	\$ 25,000	0.0%	\$ 58,500	0.0%
Other Expenses/Travel		\$ 20,000		0.3%	\$ 20,000	0.1%	\$ 40,000	0.1%	\$ 40,000	0.1%	\$ 120,000	0.1%
OTC/Edgar/Pacific Stock Transfer		\$ 32,000		0.6%	\$ 32,000	0.1%	\$ 3,200	0.0%	\$ 3,200	0.0%	\$ 70,400	0.0%
4 years - Clinical Research		\$ 1,924,372		34%	\$ 7,933,852	26.2%	\$ 5,925,020	9.6%	\$ 6,074,875	7.8%	\$ 21,858,119	12.4%
Total Costs and expenses		\$ (6,173,852)		-108%	\$ (30,210,877)	-100.0%	\$ (45,334,084)	-73.7%	\$ (55,832,828)	-71.5%	\$ (137,551,640)	-78.3%
Net Revenues		\$ (458,852)		-8.0%	\$ 1,264,123	4.2%	\$ 17,445,816	28.4%	\$ 23,556,557	30.1%	\$ 41,807,645	23.8%
Other Income/Funding		\$ 1,250,000		\$ 1,250,000	\$ 1,250,000	\$ 1,250,000	\$ 1,250,000	\$ 1,250,000	\$ 5,000,000	\$ 5,000,000	\$ 5,000,000	
Total		\$ 791,148		\$ 2,514,123	\$ 18,695,816	\$ 24,806,557	\$ 46,807,645					
EBITDA		\$ 791,148		13.8%	\$ 2,514,123	8.3%	\$ 18,695,816	30.4%	\$ 24,806,557	31.7%	\$ 46,807,645	26.7%
5 Yrs Depreciation		\$ 741,445		13.0%	\$ 1,341,445	4.4%	\$ 447,148	0.7%	\$ 447,148	0.6%	\$ 2,235,741	1.3%
EBIT - Operating Income		\$ 49,703		0.9%	\$ 1,172,678	3.9%	\$ 18,248,668	29.7%	\$ 24,359,409	31.2%	\$ 43,780,756	24.9%
Pretax Income		\$ 49,703		0.9%	\$ 1,172,678	3.9%	\$ 18,248,668	29.7%	\$ 24,359,409	31.2%	\$ 43,830,459	25.0%
30% Taxes		\$ 14,911		0.3%	\$ 351,804	1.2%	\$ 5,474,600	8.9%	\$ 7,307,823	9.4%	\$ 13,149,138	7.5%
Note Discount Expenses		\$ (600,000)		-10.5%								
Net Income / (Loss)		\$ (535,386)		-9.4%	\$ 820,875	2.7%	\$ 12,774,068	20.8%	\$ 17,051,586	21.8%	\$ 30,111,144	17.1%

We want patients to look
at *YOU* and *US* and say:

“BECAUSE OF YOU,
I DIDN'T GIVE UP!”



Join us if you desire a world with better health and a better future!

For more information, please contact us:

CBIH

ir@cbih.net

214-733-0868

